|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Capitalization1 |
87 528 | 94 860 | 132 331 | 139 651 | 139 651 | - |
| Entreprise Value (EV)2 |
102 011 | 109 142 | 144 340 | 152 889 | 151 319 | 148 864 |
| P/E ratio |
29,2x | 44,0x | 97,9x | 42,5x | 29,8x | 21,8x |
| Yield |
4,05% | 3,74% | 2,78% | 2,65% | 2,69% | 2,78% |
| Capitalization / Revenue |
3,90x | 4,29x | 5,43x | 5,29x | 4,59x | 4,04x |
| EV / Revenue |
4,54x | 4,94x | 5,92x | 5,79x | 4,98x | 4,30x |
| EV / EBITDA |
15,2x | 15,3x | 21,6x | 18,8x | 15,1x | 11,8x |
| Price to Book |
5,85x | 7,61x | 10,00x | 11,0x | 9,80x | 8,11x |
| Nbr of stocks (in thousands) |
1 265 982 | 1 266 812 | 1 311 913 | 1 312 669 | 1 312 669 | - |
| Reference price (USD) |
69,1 | 74,9 | 101 | 106 | 106 | 106 |
| Last update |
02/02/2018 | 02/14/2019 | 02/14/2020 | 01/22/2021 | 01/22/2021 | 01/22/2021 |
|
1 GBP in Million 2 USD in Million Estimates
|
|
| Income Statement Evolution | |
|
|
|
| Annual Income Statement Data |
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Net sales1 |
22 465 | 22 090 | 24 384 | 26 404 | 30 409 | 34 587 |
| EBITDA1 |
6 713 | 7 140 | 6 686 | 8 122 | 10 043 | 12 575 |
| Operating profit (EBIT)1 |
6 855 | 5 672 | 6 436 | 7 431 | 9 132 | 11 260 |
| Operating Margin |
30,5% | 25,7% | 26,4% | 28,1% | 30,0% | 32,6% |
| Pre-Tax Profit (EBT)1 |
2 227 | 1 993 | 1 548 | 4 433 | 6 244 | 8 826 |
| Net income1 |
3 001 | 2 155 | 1 335 | 2 955 | 4 577 | 6 439 |
| Net margin |
13,4% | 9,76% | 5,47% | 11,2% | 15,1% | 18,6% |
| EPS2 |
2,37 | 1,70 | 1,03 | 2,50 | 3,57 | 4,87 |
| Dividend per Share2 |
2,80 | 2,80 | 2,80 | 2,82 | 2,87 | 2,95 |
| Last update |
02/02/2018 | 02/14/2019 | 02/14/2020 | 01/20/2021 | 01/20/2021 | 01/20/2021 |
|
1 USD in Million 2 USD Estimates
|
|
|
|
|
Fiscal Period: December
|
2017 |
2018 |
2019 |
2020 |
2021 |
2022 |
| Net Debt1 |
14 483 | 14 282 | 12 009 | 13 238 | 11 668 | 9 213 |
| Net Cash position1 |
- | - | - | - | - | - |
| Leverage (Debt / EBITDA) |
2,16x | 2,00x | 1,80x | 1,63x | 1,16x | 0,73x |
| Free Cash Flow1 |
2 252 | 1 575 | 1 990 | 4 627 | 6 632 | 7 925 |
| ROE (Net Profit / Equities) |
36,4% | 32,0% | 35,6% | 39,7% | 47,2% | 54,9% |
| Shareholders' equity1 |
8 250 | 6 742 | 3 752 | 7 448 | 9 697 | 11 720 |
| ROA (Net Profit / Asset) |
4,77% | 7,07% | 2,19% | 7,68% | 11,1% | 13,9% |
| Assets1 |
62 940 | 30 480 | 61 015 | 38 488 | 41 066 | 46 262 |
| Book Value Per Share2 |
11,8 | 9,84 | 10,1 | 9,67 | 10,9 | 13,1 |
| Cash Flow per Share2 |
2,82 | 2,07 | 2,28 | 3,65 | 5,13 | 6,64 |
| Capex1 |
1 326 | 1 043 | 979 | 1 101 | 1 202 | 1 340 |
| Capex / Sales |
5,90% | 4,72% | 4,01% | 4,17% | 3,95% | 3,87% |
| Last update |
02/02/2018 | 02/14/2019 | 02/14/2020 | 01/22/2021 | 01/22/2021 | 01/22/2021 |
|
1 USD in Million 2 USD Estimates
|
|
|
|
|
|
Financial data source
© 2021 S&P Global Market Intelligence
|
|
|
AstraZeneca : Foreigners net sellers of Asian equities in 2020, despite fourth-quarter turnaround |
Capitalization (GBP) 102 086 246 665 Capitalization (USD) 139 483 046 175 Net sales (USD) 24 384 000 000 Number of employees 70 600 Sales / Employee (USD) 345 382 Free-Float capitalization (GBP) 97 743 080 769 Free-Float capitalization (USD) 133 548 867 684 Avg. Exchange 20 sessions (USD) 16 542 816 796 Average Daily Capital Traded 16,2%
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Evolution Valeur d'Entreprise / EBITDA
|
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
